Capricor Therapeutics (CAPR) Change in Accured Expenses (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Change in Accured Expenses of -$3.1 million for Q1 2026, down 334.27% year-over-year from $1.3 million in Q1 2025, and down 242.11% quarter-over-quarter from $2.2 million in Q4 2025.
Capricor Therapeutics (CAPR) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$3.1 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 334.27% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at $1.6 million (down 51.28% YoY), while the FY2025 annual figure was $6.0 million, up 208.27% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$3.1 million, down from $2.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.2 million in Q4 2025, with the low at -$3.1 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is $501815.0 (2023), against an average of $464028.2.
- The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses surged 83134.6% in 2025, then slumped 334.27% in 2026.
- Capricor Therapeutics' Change in Accured Expenses stood at $982327.0 in 2022, then plunged by 155.15% to -$541709.0 in 2023, then surged by 406.44% to $1.7 million in 2024, then surged by 30.61% to $2.2 million in 2025, then sank by 242.11% to -$3.1 million in 2026.
- Business Quant data shows CAPR's Change in Accured Expenses at -$3.1 million in Q1 2026, $2.2 million in Q4 2025, and $971647.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | -3.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.08 Mn |
| Mar 31, 2026 | -3.08 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 971,647.00 |
| Sep 30, 2025 | 971,647.00 |
| Jun 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 361,429.00 |
| Sep 30, 2024 | 361,429.00 |
| Jun 30, 2024 | -78,723.00 |
| Jun 30, 2024 | -78,723.00 |
| Mar 31, 2024 | -1,584.00 |
| Mar 31, 2024 | -1,584.00 |
| Dec 31, 2023 | -541,709.00 |
| Dec 31, 2023 | -541,709.00 |